Bicycle Therapeutics plc (FRA:50BA)
4.500
0.00 (0.00%)
At close: Mar 18, 2026
Bicycle Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 628.11 | 879.52 | 526.42 | 339.15 | 438.68 |
Cash & Short-Term Investments | 628.11 | 879.52 | 526.42 | 339.15 | 438.68 |
Cash Growth | -28.59% | 67.07% | 55.22% | -22.69% | 222.58% |
Accounts Receivable | - | - | - | 2.05 | 1 |
Other Receivables | 35.59 | 35.65 | 24.04 | 19.16 | 10.91 |
Receivables | 35.59 | 35.65 | 24.04 | 21.21 | 11.91 |
Prepaid Expenses | 19.18 | 13.43 | 11.41 | 9.02 | 7.97 |
Total Current Assets | 682.89 | 928.61 | 561.87 | 369.38 | 458.56 |
Property, Plant & Equipment | 21.91 | 17.19 | 27.68 | 32.77 | 17.79 |
Other Long-Term Assets | 12.81 | 11.07 | 5.79 | 8.46 | 3.45 |
Total Assets | 717.6 | 956.87 | 595.34 | 410.61 | 479.79 |
Accounts Payable | 9.67 | 15.79 | 13.05 | 6.47 | 2.72 |
Accrued Expenses | 41.46 | 35.45 | 26.38 | 21.86 | 11.29 |
Current Portion of Leases | 2.76 | 5.5 | 4.88 | 3.13 | 2.38 |
Current Unearned Revenue | 2.96 | 10.19 | 24.98 | 20.42 | 19.27 |
Other Current Liabilities | 0.14 | 0.3 | 0.26 | 1.47 | 0.57 |
Total Current Liabilities | 56.98 | 67.23 | 69.54 | 53.34 | 36.24 |
Long-Term Debt | - | - | 30.7 | 30.32 | 29.87 |
Long-Term Leases | 14.1 | 3.99 | 9.38 | 10.89 | 12.08 |
Long-Term Unearned Revenue | 35.51 | 91.47 | 110.22 | 41.46 | 52.07 |
Other Long-Term Liabilities | 1.03 | 1.12 | 4.58 | 3.83 | 3.28 |
Total Liabilities | 107.62 | 163.81 | 224.41 | 139.83 | 133.54 |
Common Stock | 0.89 | 0.89 | 0.55 | 0.39 | 0.38 |
Additional Paid-In Capital | 1,512 | 1,473 | 883.45 | 601.11 | 567.64 |
Retained Earnings | -899.75 | -680.79 | -511.76 | -331.1 | -218.38 |
Comprehensive Income & Other | -3.51 | 0.12 | -1.3 | 0.39 | -3.39 |
Total Common Equity | 609.98 | 793.06 | 370.93 | 270.78 | 346.25 |
Shareholders' Equity | 609.98 | 793.06 | 370.93 | 270.78 | 346.25 |
Total Liabilities & Equity | 717.6 | 956.87 | 595.34 | 410.61 | 479.79 |
Total Debt | 16.85 | 9.49 | 44.96 | 44.33 | 44.34 |
Net Cash (Debt) | 611.26 | 870.03 | 481.47 | 294.83 | 394.34 |
Net Cash Growth | -29.74% | 80.70% | 63.30% | -25.24% | 228.03% |
Net Cash Per Share | 8.82 | 14.95 | 13.53 | 9.94 | 15.73 |
Filing Date Shares Outstanding | 69.71 | 69.2 | 42.59 | 30.02 | 29.6 |
Total Common Shares Outstanding | 69.37 | 69.06 | 42.43 | 29.87 | 29.58 |
Working Capital | 625.9 | 861.38 | 492.33 | 316.04 | 422.32 |
Book Value Per Share | 8.79 | 11.48 | 8.74 | 9.06 | 11.71 |
Tangible Book Value | 609.98 | 793.06 | 370.93 | 270.78 | 346.25 |
Tangible Book Value Per Share | 8.79 | 11.48 | 8.74 | 9.06 | 11.71 |
Machinery | 19.06 | 16.53 | 16.91 | 16.24 | 7.11 |
Leasehold Improvements | 12.03 | 10.9 | 11 | 10.74 | 0.81 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.